AbbVie knows immunology better than almost anyone. Humira made the company more than $200 billion before it went off patent. Skyrizi and Rinvoq are growing faster than Humira is declining. And now zumilokibart gives AbbVie a shot at the next generation of eczema and asthma treatment with a dosing profile that could fundamentally change how patients experience their disease.
The math is simple. Dupixent requires an injection every two weeks. That is 26 shots a year. Zumilokibart’s Phase 2 data support dosing every three to six months. That is two to four shots a year. Sanofi and Regeneron’s Dupixent generated $14 billion in 2025 revenue. Guggenheim doubled their peak sales estimate for zumilokibart to $5.2 billion after the Phase 2 data in March. AbbVie paid $10.9 billion in cash at a 49% premium to make it theirs. Both boards approved unanimously. Close expected Q3 2026. ABBV shares rose 6.9% on the news.
This is AbbVie’s biggest acquisition since the $63 billion Allergan deal in 2020. It pushes the number of billion dollar biotech deals this year to 33 and total 2026 M&A to just under $134 billion. BioPharma Dive called it the sector’s second largest deal of 2026 behind GSK’s $10.6 billion Nuvalent acquisition. Meanwhile, Merck’s tulisokibart hit Phase 3 in ulcerative colitis, and BIO International is underway in San Diego with more than 20,000 attendees.
AbbVie Acquires Apogee for $10.9B to Challenge Dupixent
Three weeks ago, Apogee locked in $1.3 billion in non dilutive financing from Blackstone to fund zumilokibart development on its own. Three weeks later, AbbVie showed up with $10.9 billion and ended the conversation. Blackstone’s investors are having a very good week.
Why the Dosing Profile Changes Everything
Zumilokibart is an extended half life anti IL 13 monoclonal antibody being developed for atopic dermatitis, asthma, and other inflammatory conditions. In Phase 2, approximately two thirds of patients achieved significant skin clearance at 16 weeks with concurrent improvement in itch and disease control. The longer term data support maintenance dosing of either once every three months or twice a year.
That dosing advantage is not incremental. It is transformational. Think about what it means for an eczema patient. Atopic dermatitis is a chronic disease that often begins in childhood and can last a lifetime. A patient on Dupixent commits to an injection every two weeks, every month, every year, for as long as they want their disease controlled. Over a decade, that is 260 injections. Over a lifetime, the number runs into the thousands. Patients deal with injection site reactions, the logistical burden of keeping a biologic refrigerated, the psychological weight of a biweekly medical routine, and the occasional missed dose that lets symptoms flare.
Now imagine the same patient getting four shots a year. Or two. The disease control is the same or better (cross trial comparisons suggest zumilokibart can match or improve on the efficacy of both Dupixent and Lilly’s Ebglyss), but the treatment experience is fundamentally different. The patient thinks about their eczema four times a year instead of twenty six. That changes adherence. That changes quality of life. And that changes the commercial trajectory of a $14 billion market.
Yale’s Dr. Christopher Bunick said the deal “is going to send shock waves through the AD community.” He is probably right.
Why AbbVie Is the Right Buyer
AbbVie is not entering immunology. It is the immunology company. The Humira franchise taught AbbVie how to build, sell, and defend a biologic in autoimmune disease better than any company on earth. Skyrizi and Rinvoq are the successors. The commercial infrastructure, the physician relationships in dermatology and respiratory medicine, and the payer contracting expertise are all in place.
JPMorgan said AbbVie will be able to “leverage its historic strength in immunology” to push zumilokibart through Phase 3 and commercialization. BMO said the deal “fits naturally” with AbbVie’s portfolio. Fierce Biotech reported it “will give AbbVie control of a late phase eczema drug candidate that could pose a threat to Eli Lilly, Regeneron and Sanofi.”
Phase 3 studies start this year. If the efficacy and dosing profile hold at the registrational level, zumilokibart could reach the market by 2028 or 2029. That timing matters because Dupixent’s biosimilar competition is expected to begin in the late 2020s, creating a window where a next generation product with dramatically better convenience could capture patients transitioning away from branded Dupixent.
Our Pro brief analyzes why two to four injections per year could reshape the $14B eczema and asthma market, assesses the adherence and persistence advantages of extended dosing, and models the peak sales potential against Dupixent’s franchise. [Details below.]
The Blackstone Angle
Three weeks ago, we covered the Apogee/Blackstone $1.3 billion non dilutive financing. At the time, we described it as “one of the largest non dilutive biotech financings of 2026” and noted it gave Apogee a runway to pursue pivotal development and launch without additional equity dilution. The deal was structured to give Blackstone exposure to zumilokibart’s commercial potential through milestone payments.
AbbVie’s $10.9 billion acquisition changes the economics entirely. Blackstone’s structured investment is now superseded by an outright acquisition at a 49% premium. The Blackstone investors who committed capital just three weeks ago are looking at an immediate return that most structured biotech financings take years to deliver. The sequencing—Blackstone deal, then AbbVie acquisition—suggests Apogee’s board may have been running a dual track process, or AbbVie may have moved quickly after seeing the Blackstone financing as a signal that the asset was attracting serious capital attention.
Merck’s Tulisokibart Hits Phase 3 in Ulcerative Colitis
Merck announced that tulisokibart met the primary and key secondary endpoints in the Phase 3 ATLAS UC induction study in patients with moderately to severely active ulcerative colitis.
Why Anti TL1A Matters
Tulisokibart is an anti TL1A antibody, and TL1A is emerging as one of the most important new targets in inflammatory bowel disease. The mechanism has attracted enormous industry investment: Roche paid $7.1 billion for Telavant’s RVT 3101 (an anti TL1A antibody) in 2024, making it one of the largest acquisitions for a single clinical asset in recent years.
The Phase 3 confirmation that tulisokibart works at the registrational level is significant for two reasons. First, it validates the anti TL1A mechanism in a large randomized controlled trial, providing the evidence that the Phase 2 data from Prometheus (which Merck acquired) promised but could not confirm alone. Second, it gives Merck a strong entry into the inflammatory bowel disease market at a time when the company desperately needs pipeline diversification beyond Keytruda.
Keytruda faces patent cliff exposure in 2028. Merck has been building its post Keytruda portfolio through the sac TMT ADC partnership with Kelun Biotech, the 4E Therapeutics non opioid pain acquisition, and internal pipeline development. Adding a validated IBD asset through tulisokibart gives the company another therapeutic area with blockbuster potential that does not depend on the oncology franchise facing genericization.
The IBD treatment landscape is large and competitive. Current biologics include Humira biosimilars, J&J’s Stelara, Takeda’s Entyvio, AbbVie’s Rinvoq and Skyrizi, and several others. Despite these options, substantial unmet need remains, particularly in patients who cycle through multiple therapies without achieving adequate disease control. Anti TL1A offers a new mechanism that could work where existing approaches fall short.
The competitive dynamics around TL1A are worth watching. Roche’s $7.1 billion Telavant asset and Merck’s tulisokibart are both targeting the same mechanism. If both reach the market, the anti TL1A class will have two major players competing for IBD market share with differentiated clinical datasets. For patients, more competition on a validated mechanism means more treatment options and potentially better outcomes as physicians gain experience with the new class. For investors, it means the commercial opportunity will be divided, but the total market for anti TL1A therapy could exceed what either company captures individually because a validated mechanism with multiple approved options tends to expand physician confidence and patient access faster than a single product can.
The anti TL1A story also illustrates a pattern we have seen repeatedly in 2026: the validation of a new mechanism by one company creates competitive urgency for every other company in the space. Roche’s $7.1 billion Telavant deal signaled that anti TL1A was commercially viable. Merck’s Phase 3 confirmation now proves the mechanism works at the registrational level. Other companies developing TL1A programs will accelerate their timelines in response. The window between mechanism validation and competitive saturation is getting shorter every year.
$134B in M&A and BIO International Is Just Getting Started
The AbbVie/Apogee deal pushes 2026 M&A further into territory that has no modern precedent. 33 deals have exceeded $1 billion this year. Total value sits just under $134 billion. Three weeks ago, CNBC reported $106 billion. GSK/Nuvalent added $10.6 billion. AbbVie/Apogee adds $10.9 billion. Incyte/Vega, Biogen/RayThera, and dozens of smaller transactions fill in the rest.
For context, PwC’s midyear report called the ecosystem “back to full health” and counted $65 billion in Q1 alone. Forbion said companies are “buying stuff like it’s going out of fashion.” AbbVie is proving both right with its third billion dollar plus acquisition of 2026.
And BIO International is underway in San Diego with more than 20,000 attendees and 130 sessions across 18 focus areas. Hundreds of partnering meetings are happening this week. The energy at BIO reflects the broader market. When M&A exceeds $130 billion, when IPOs have raised $4.1 billion, when PwC declares the ecosystem healthy, and when every major pharma company has deals in the pipeline, the partnering conversations at a conference like BIO carry weight that they do not carry in leaner years. Companies are not just talking about deals. They are closing them. The Lilly, Pfizer, BMS, Merck, GSK, and AbbVie business development teams that are walking the San Diego convention center this week have the budgets and the board mandates to make transactions happen. The deals that get announced in the coming days and weeks often trace their origins to conversations that started at BIO.
Strategic Themes
1. AbbVie Is Building the Next Generation Immunology Franchise Before Dupixent’s Biosimilars Arrive
Timing matters. Dupixent biosimilar competition is expected to begin in the late 2020s. A next generation product with dramatically better convenience (two to four shots versus 26) could intercept patients as they transition away from branded Dupixent and capture share before biosimilars commoditize the market. AbbVie timed the Humira to Skyrizi/Rinvoq transition effectively. The zumilokibart acquisition suggests the company is running the same playbook against someone else’s franchise this time.
2. The Dosing Revolution in Biologics Is Becoming a Competitive Differentiator Across Disease Areas
Zumilokibart at two to four injections per year versus Dupixent at 26. This is not a minor convenience improvement. It is a category defining advantage that changes how patients experience chronic disease management. The technology behind it—extended half life engineering that keeps an antibody active in the body for months instead of weeks—is not unique to zumilokibart. If the approach can deliver comparable efficacy with dramatically fewer injections in eczema, the same engineering principle can be applied across every chronic biologic indication: psoriasis, rheumatoid arthritis, asthma, inflammatory bowel disease, and beyond.
The companies investing in long acting formulations and extended half life platforms will have a structural advantage over those relying on traditional biweekly or monthly dosing schedules. Patients prefer fewer injections. Physicians prefer better adherence. Payers prefer sustained outcomes that reduce hospitalizations and disease flares. When the data show that you can get all three—fewer shots, better adherence, sustained disease control—the clinical and commercial argument is overwhelming. AbbVie just bet $10.9 billion that this is the future of chronic disease biologics. That bet is likely to prove right.
3. Merck’s Post Keytruda Diversification Is Producing Results Across Multiple Therapeutic Areas
sac TMT in oncology (two Phase 3 wins). Tulisokibart in IBD (Phase 3 positive). 4E Therapeutics in pain (13th deal for Lilly, but Merck is building its own pain portfolio through internal programs). The Keytruda patent cliff creates existential urgency, and Merck is responding with a pipeline diversification strategy that spans oncology, immunology, and pain. The tulisokibart data are particularly important because they give Merck a validated asset outside oncology for the first time in years.
4. $134B in M&A Means the Second Half Starts from an Unprecedented Base
If deal flow merely continues at the first half pace, 2026 finishes above $250 billion. If it accelerates (BIO International catalysts, Revolution approval triggering KRAS deals, Medicare Bridge launch clarifying GLP 1 market sizing), the total could approach levels never seen in biopharma. Every indicator, from PwC to deal count to IPO proceeds to conference partnering volume, points in the same direction: this is a structural M&A cycle driven by patent cliff necessity and funded by the cash flows of the industry’s most profitable franchises.
Frequently Asked Questions
What is the AbbVie/Apogee deal?
AbbVie is acquiring Apogee Therapeutics for $10.9 billion ($135.11 per share, 49% premium) to get zumilokibart, an extended half life anti IL 13 antibody for eczema and asthma that could need as few as two to four injections per year versus Dupixent’s 26. AbbVie’s biggest deal since Allergan. Close expected Q3 2026.
How does zumilokibart compare to Dupixent?
Dupixent requires injection every two weeks (26 per year). Zumilokibart’s Phase 2 data support dosing every three to six months (two to four per year). Cross trial comparisons suggest comparable or improved efficacy. Guggenheim projects $5.2 billion in peak sales. Dupixent generated $14 billion in 2025.
What happened with Apogee’s Blackstone deal?
Three weeks ago, Apogee locked in $1.3 billion in non dilutive financing from Blackstone to fund development independently. AbbVie’s $10.9 billion acquisition at a 49% premium supersedes that arrangement. Blackstone’s investors receive an immediate return on capital committed just three weeks earlier.
What is Merck’s tulisokibart?
An anti TL1A antibody that met Phase 3 endpoints in ulcerative colitis (ATLAS UC study). TL1A is emerging as one of the most important new targets in inflammatory bowel disease. Roche paid $7.1 billion for a competing anti TL1A asset through the Telavant acquisition.
How much total M&A has occurred in 2026?
Just under $134 billion across 33 deals exceeding $1 billion. Up from the $106 billion CNBC reported three weeks ago. The year is on pace to be the strongest in biopharma M&A history.
What is happening at BIO International?
The convention is underway in San Diego through June 25 with more than 20,000 attendees and 130 sessions. Hundreds of partnering meetings are happening this week. We will cover significant announcements daily.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
AbbVie’s Dupixent Challenge. We analyze why two to four injections per year could reshape the $14 billion eczema and asthma market, model the adherence and persistence advantages of extended dosing, and assess Guggenheim’s $5.2 billion peak sales estimate against the Dupixent franchise trajectory.
$134B and Counting. We compile the full 2026 M&A scorecard at 33 billion dollar deals and assess what the pace tells us about second half expectations, BIO International deal flow, and the structural drivers sustaining the cycle.
Anti TL1A. We analyze how Merck’s tulisokibart Phase 3 data set up a competitive race with Roche’s Telavant asset, model the IBD market opportunity for both programs, and assess how the anti TL1A mechanism differentiates from existing biologics in ulcerative colitis.
Plus: Blackstone deal economics, AbbVie immunology franchise map, Keytruda diversification tracker, BIO International daily coverage, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
